Repare Therapeutics
RPTX
RPTX was delisted on the 27th of January, 2026.
46 hedge funds and large institutions have $65.4M invested in Repare Therapeutics in 2025 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 8 increasing their positions, 8 reducing their positions, and 11 closing their positions.
55% more call options, than puts
Call options by funds: $872K | Put options by funds: $564K
36% more capital invested
Capital invested by funds: $48M → $65.4M (+$17.4M)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
18% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 11
2% more funds holding
Funds holding: 45 → 46 (+1)
0% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 8
5.11% less ownership
Funds ownership: 63.49% → 58.37% (-5.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$2.25M |
| 2 |
RC
Rangeley Capital
New Canaan,
Connecticut
|
+$1.29M |
| 3 |
Two Sigma Investments
New York
|
+$650K |
| 4 |
Jane Street
New York
|
+$560K |
| 5 |
YCM
Yakira Capital Management
Westport,
Connecticut
|
+$537K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VVM
Versant Venture Management
San Francisco,
California
|
-$4.66M |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
-$1.44M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$927K |
| 4 |
AAA
Affinity Asset Advisors
New York
|
-$352K |
| 5 |
Stifel Financial
St. Louis,
Missouri
|
-$136K |
RPTX Hedge Fund Activity: Q4 2025 in Review
46 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Repare Therapeutics (RPTX) for Q4 2025, worth a combined $65.4M — up 36% from $48M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new RPTX positions and 11 closed out — a net gain of 2 holders — while 8 added to existing stakes and 8 trimmed.
The largest buyer was Marshall Wace, opening a new position worth an estimated $2.25M. The largest seller was Versant Venture Management, exiting entirely with an estimated $4.66M sold.
- 46 institutional investors held Repare Therapeutics (RPTX) as of Q4 2025, up from 45 in Q3 2025.
- Funds reported $65.4M of Repare Therapeutics stock for Q4 2025, up 36% quarter-over-quarter.
- 13 funds opened new Repare Therapeutics positions in Q4 2025 and 11 closed out, a net change of +2 holders.
- The largest Repare Therapeutics buyer in Q4 2025 was Marshall Wace, an estimated $2.25M added.
- The largest Repare Therapeutics seller in Q4 2025 was Versant Venture Management, an estimated $4.66M sold.
Based on aggregated 13F filings for Q4 2025.